CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 61 enrolled
Drug / intervention
68Ga-PSMA-11 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02673151
NCT02673151Phase 3Completed
CompareCT.gov

68-Ga PSMA 11 PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy in Patients With Elevated PSA

Andrei Iagaru·interventional·Posted Feb 3, 2016·Updated Jan 13, 2022

In Brief

A Phase 3 clinical trial evaluating Computed Tomography (CT) scan, 68Ga-PSMA-11, and 1 other intervention for Prostate Adenocarcinoma and 2 related conditions. Completed, enrolled 61 participants across 1 site.

Detailed Summary

The purpose of this research study is to see if recurrent prostate cancer can be identified using a special procedure called a positron emission tomography (PET) scan. PET/CT is used to describe information regarding the function, as well as location and size of a tumor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 3, 2016
Enrollment StartMay 20, 2017
Primary CompletionApr 27, 2018
Study CompletionApr 27, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.4 years ago

Interventions

Computed Tomography (CT) scanprocedure

PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).

68Ga-PSMA-11drug

68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11), administered by intravenous (IV) injection.

Positron Emission Tomography (PET)procedure

PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).